التفاصيل البيبلوغرافية
| العنوان: |
Real-Life Data Comparing Weekly VCD and Twice-Weekly VCD Protocols in Newly Diagnosed Multiple Myeloma Patients. |
| المؤلفون: |
Cengiz, Esra, Can, Ferda, Güneş, Ahmet Kürşad, Ceran, Funda, Dağdaş, Simten, Özet, Gülsüm, Dilek, İmdat |
| المصدر: |
Turkish Journal of Internal Medicine; Jan2024, Vol. 6 Issue 1, p51-57, 7p |
| مصطلحات موضوعية: |
BORTEZOMIB, MULTIPLE myeloma, CYCLOPHOSPHAMIDE, DEXAMETHASONE, THERAPEUTICS |
| مستخلص: |
Background This study aimed to evaluate the efficacy and side effects of bortezomib, cyclophosphamide and dexamethasone (VCD) treatment, which is frequently preferred in primary care in patients with multiple myeloma in our country, with two applications per week and one application per week. Methods A total of 141 patients who received VCD in the induction treatment of newly diagnosed multiple myeloma were retrospectively reviewed and analysed. Both treatment groups were evaluated in terms of efficacy and side effects. Results A total of 141 patients with newly diagnosed multiple myeloma who received VCD in induction therapy were included in the study. The median age was 62 years. Among 141 patients included in the study, 57 patients received treatment two days a week and 84 patients received treatment one day a week. Sixty-one (43.3%) patients were female and 80 (56.7%) were male. There was no significant difference between the two groups in terms of post-treatment response rates after 2nd cycle VCD regimen (p=0.378) and 4th cycle VCD regimen (p=0.965). Patients receiving weekly VCD regimen had a significantly higher rate of receiving other regimens, and additional VCD regimen of autologous stem cell transplant (ASCT) was significantly higher in patients who received a VCD regimen twice a week compared to the other group (p<0.001). ASCT was performed in 73% of the patients (n: 103). In 54 patients with ASCT at the end of 4th cycle VCD, there was no significant difference between very good partial response/complete response rates and partial response/sub responses between the two groups according to the 3rd month post-transplant responses (p=0.612). Neuropathy was observed in seven (12.3%) patients receiving twice-weekly VCD regimens, while neuropathy was observed in 16 (19.3%) and neutropenia in two (2.4%) patients receiving weekly VCD regimens. The two groups had no significant difference regarding side effects (p=0.387). Conclusion Our study found no significant difference in the treatment response rates of patients receiving weekly VCD and twice-weekly VCD. The low rates of ASCT in the weekly VCD group were thought to be related to the fact that the patients receiving the weekly regimen were older than the other group and were unsuitable for ASCT due to age. No difference was observed between the two groups regarding the frequency of side effects. [ABSTRACT FROM AUTHOR] |
|
Copyright of Turkish Journal of Internal Medicine is the property of Nizameddin KOCA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |